Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells $143,979.90 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 18,895 shares of Relay Therapeutics stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $143,979.90. Following the completion of the transaction, the insider directly owned 422,733 shares of the company’s stock, valued at $3,221,225.46. This represents a 4.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Relay Therapeutics Trading Down 0.6%

Shares of RLAY stock opened at $7.66 on Friday. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -4.38 and a beta of 1.55. The firm’s 50 day moving average is $7.97 and its 200-day moving average is $5.99. Relay Therapeutics, Inc. has a 1 year low of $1.77 and a 1 year high of $9.04.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, equities research analysts forecast that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on RLAY shares. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective on the stock in a research note on Monday, January 26th. Finally, Wells Fargo & Company raised shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $6.00 to $13.00 in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Institutional Trading of Relay Therapeutics

Large investors have recently bought and sold shares of the business. Commodore Capital LP bought a new position in Relay Therapeutics in the second quarter valued at approximately $46,191,000. TCG Crossover Management LLC bought a new stake in Relay Therapeutics in the 3rd quarter valued at $9,450,000. Woodline Partners LP boosted its stake in Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after purchasing an additional 1,241,657 shares during the period. Bellevue Group AG increased its holdings in Relay Therapeutics by 11.6% during the 2nd quarter. Bellevue Group AG now owns 8,230,870 shares of the company’s stock worth $28,479,000 after purchasing an additional 853,578 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Relay Therapeutics in the 2nd quarter valued at about $2,892,000. 96.98% of the stock is owned by institutional investors.

Relay Therapeutics News Roundup

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Technical/quote signal — MarketBeat notes an intraday uptick and that shares are trading above the 200‑day moving average, a constructive technical sign that can attract momentum buyers. MarketBeat RLAY quote
• Positive Sentiment: Analyst support — Recent upgrades (Oppenheimer to Outperform; Wells Fargo to Overweight) and a consensus “Moderate Buy” rating give fundamental/flow support that can limit downside from short‑term selling. Analyst commentary
• Neutral Sentiment: Insiders still hold large stakes — filings show executives retain hundreds of thousands of shares after the sales, so these transactions reduce ownership modestly but are not a change of control signal. (See SEC filings for details.) SEC ownership filing
• Negative Sentiment: CFO selling — CFO Thomas Catinazzo sold 13,820 shares on Jan. 27 (~$105k at ~$7.62) and an additional 1,695 shares on Jan. 28 (~$14.3k at ~$8.45). Multi‑day sales by the CFO amplify concerns and can sap near‑term sentiment. Catinazzo filings
• Negative Sentiment: Other insider sales clustered over Jan. 27–28 — Director/executive Peter Rahmer sold ~11.7k and 1,354 shares across two days; Donald Bergstrom sold ~18.9k and 2,686 shares. The concentration and timing of sales by multiple insiders increase short‑term selling pressure. Rahmer filings Bergstrom filings
• Negative Sentiment: Market commentary citing a notable intraday decline (~5.2%) amplifies negative sentiment and may trigger momentum selling even if fundamentals are unchanged. Why RLAY is down 5.18%

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.